Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode.

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH).

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

CRISPR Therapeutics

Intellia Therapeutics

Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.

3 Gene Editing Stocks with Potential to Transform Medicine

Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in precision genetic medicines, which is a growing and viable market.

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

Vertex Pharmaceuticals

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.

Beam Therapeutics Announces Transition of Chief Financial Officer

Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now

Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

Booking Hlds

Vici Properties

In recent months, markets have reached new record highs, signaling that high-growth potential stocks offer opportunities to multiply earnings. The number of high-wealth individuals in the U.S. grew substantially last year alongside the stock market, partly due to notable gains among artificial intelligence (AI) stocks.

3 Stocks With the Potential to 10X Your Money

Arcellx

Mind Medicine MindMed

The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

Lilium BV

Recursion Pharmaceuticals

Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.

3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.

You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial.

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid Congress. The optimized process is deployed for the manufacturing of BEAM-101 in the BEACON Phase 1/2 clinical trial in patients with severe sickle cell disease (SCD), and the data include both preclinical and GMP clinical manufacturing experience to date.

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

News for Beam Therapeutics Stock (BEAM)